四季抗病毒合剂联合重组人干扰素α1b注射液治疗小儿上呼吸道感染的疗效观察

Clinical observation of Siji Kangbingdu Mistura combined with Recombinant Human Interferon α1b Injection in treatment of children with upper respiratory tract infection

目的探讨四季抗病毒合剂联合重组人干扰素α1b注射液治疗小儿上呼吸道感染的临床疗效。方法选取2015年1月—2016年1月成都市金牛区妇幼保健院儿科收治的上呼吸道感染患儿86例,根据治疗方案的不同分为对照组和治疗组,每组各43例。对照组患儿雾化吸入重组人干扰素α1b注射液,1~2岁5μg/次,2~6岁10μg/次,6~7岁20μg/次,加入生理盐水4 m L,15 min/次,2次/d。治疗组在对照组治疗基础上口服四季抗病毒合剂,1~5岁5 m L/次,5~7岁7.5 m L/次,3次/d。两组患儿均连续治疗5 d。观察两组的临床疗效,同时比较两组患儿退热时间、咳嗽消失时间、咽喉疼痛消失时间。结果治疗后,对照组和治疗组的总有效率分别为86.05%、93.02%,两组比较差异具有统计学意义（P〈0.05）。治疗组患儿退热时间、咳嗽消失时间以及咽喉疼痛消失时间均明显短于对照组,两组比较差异有统计学意义（P〈0.05）。结论四季抗病毒合剂联合重组人干扰素α1b注射液治疗小儿上呼吸道感染具有较好的临床疗效,可以快速缓解患儿的临床症状,不良反应少,具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Siji Kangbingdu Mistura combined with Recombinant Human Interferon α1b Injection in treatment of children with upper respiratory tract infection. Methods Children（86 cases） with upper respiratory tract infection in Jinniu District Maternal and Child Health Care Hospital of Chengdu from January 2015 to January 2016 were enrolled in this study. According to the different treatment plans, children were divided into control group（43 cases） and treatment group（43 cases）. The children in the control group were aerosol inhalation administered with Recombinant Human Interferon α1b Injection, and the 1 — 2 year old patients were given 5 μg/time, 2 — 6 year old patients were given 10 μg/time, 6 — 7 year old patients were given 20 μg/time, Recombinant Human Interferon α1b Injection added into normal saline 4 m L, 15 min/time, twice daily. The children in the treatment group were po administered with Siji Kangbingdu Mistura on the basis of control group, 1 — 5 year old patients were given 5 m L/time, 5 — 7 year old patients were given 7.5 m L/time, three times daily. The children in two groups were treated for 5 d. After treatment, the clinical efficacies were evaluated, and the antifebrile time, and disappearred times of cough and throat pain in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 86.05% and 93.02%, respectively, and there were differences between two groups（P〈0.05）. The antifebrile time, and disappearred times of cough and throat pain in treatment group were significantly shorter than those in the control group, with significant difference between two groups（P〈0.05）. Conclusion Siji Kangbingdu Mistura combined with Recombinant Human Interferon α1b Injection has clinical curative effect in treatment of children with upper respiratory tract infection, and can relieve clinical symptoms quickly with less adverse reaction, which has a certain clinical application value.